Cabozantinib for Patients With Recurrent or Progressive Meningioma
ConditionMeningioma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorBaptist Health South Florida
About this trial
A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma
Eligibility criteria
Qualifiers
Histologic (preferred) or radiologic diagnosis of meningioma. All World Health Organization (WHO) grades (I, II and III) are allowed.
All patients must have developed recurrent disease or progressive disease after receiving standard therapy (e.g., radiation or surgery) > 6 months ago or have been deemed ineligible to receive these therapies.
Karnofsky Performance Status ≥ 50.
Absolute Neutrophil Count ≥ 1.5 × 10^9 / L without granulocyte colony-stimulating factor support.
Disqualifiers
Prior treatment with cabozantinib.
Patients < 18 years old.
Patients who are pregnant or breast-feeding.
4. Any other active malignancy at time of first dose of study treatment or diagnosis of another malignancy within 3 years prior to first dose of study treatment that requires active treatment, except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
Trial design
Treatments tested in this trial
- Cabozantinib
Treatment groups
24 Participants
are divided into 1 treatment groupSponsors and collaborators
Baptist Health South Florida
Lead sponsor
Exelixis
Collaborator
Source ClinicalTrials.gov